Literature DB >> 12860732

Apoptosis of peripheral blood lymphocytes in patients with juvenile idiopathic arthritis.

E Smolewska1, H Brozik, P Smolewski, M Biernacka-Zielinska, Z Darzynkiewicz, J Stanczyk.   

Abstract

BACKGROUND: Recent data suggested that abnormalities in mechanisms regulating apoptosis may have a role in the development of the rheumatoid process.
OBJECTIVE: To evaluate different aspects of apoptosis in children with juvenile idiopathic arthritis (JIA).
METHODS: The frequency of TUNEL positive peripheral blood (PB) lymphocytes (apoptotic index (AI)), as well as serum CD95 (APO1/Fas) antigen expression and serum levels of sFas and interleukin 15 (IL15), were examined in 44 cases of JIA. Results were correlated with type of onset, activity of JIA, and acute phase indicators.
RESULTS: The AI of lymphocytes was significantly higher in patients with JIA than in controls (p=0.020). The mean AI of lymphocytes was increased in JIA with systemic type of onset and high activity (p=0.001). Moreover, IL15 levels in systemic disease were higher than in controls (p=0.012). An increased AI correlated with raised IL15 (p=0.046), erythrocyte sedimentation rate (p=0.005) and C reactive protein (CRP; p=0.017). Additionally, correlation was found between IL15 and CRP levels (p=0.039). CD95 and sFas levels were unchanged compared with controls.
CONCLUSION: PB lymphocytes of children with JIA have an increased tendency to undergo apoptosis. The degree of apoptosis depends on the type of onset and activity of JIA and correlates with serum levels of IL15. Further studies are needed to explain whether this is an epiphenomenon of the disease activity or is related to the pathogenesis of JIA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12860732      PMCID: PMC1754617          DOI: 10.1136/ard.62.8.761

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  7 in total

1.  Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states.

Authors:  Claudia Macaubas; Khoa Nguyen; Chetan Deshpande; Carolyn Phillips; Ariana Peck; Tzielan Lee; Jane L Park; Christy Sandborg; Elizabeth D Mellins
Journal:  Clin Immunol       Date:  2009-10-29       Impact factor: 3.969

2.  Monocytes are resistant to apoptosis in systemic juvenile idiopathic arthritis.

Authors:  Shivani Srivastava; Claudia Macaubas; Chetan Deshpande; Heather C Alexander; Sheng-Yung Chang; Yue Sun; Jane L Park; Tzielan Lee; Ann Begovich; Elizabeth D Mellins
Journal:  Clin Immunol       Date:  2010-05-11       Impact factor: 3.969

Review 3.  Targeting cytokines beyond tumor necrosis factor-alpha and interleukin-1 in rheumatoid arthritis.

Authors:  Iain B McInnes; J Alastair Gracie
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

Review 4.  Targeting cytokines beyond tumor necrosis factor-alpha and interleukin-1 in rheumatoid arthritis.

Authors:  Iain B McInnes; J Alastair Gracie
Journal:  Curr Pain Headache Rep       Date:  2005-12

Review 5.  The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases.

Authors:  Cem Gabay; Iain B McInnes
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

6.  Relationship between impaired apoptosis of lymphocytes and distribution of dendritic cells in peripheral blood and synovial fluid of children with juvenile idiopathic arthritis.

Authors:  Elzbieta Smolewska; Barbara Cebula; Henryka Brózik; Jerzy Stańczyk
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-07-29       Impact factor: 4.291

7.  Radiographic progression can still occur in individual patients with low or moderate disease activity in the current treat-to-target paradigm: real-world data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.

Authors:  Peter M Ten Klooster; Letty G A Versteeg; Martijn A H Oude Voshaar; Inmaculada de la Torre; Francesco De Leonardis; Walid Fakhouri; Liliana Zaremba-Pechmann; Mart van de Laar
Journal:  Arthritis Res Ther       Date:  2019-11-12       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.